moderate - Capital equipment purchases by psychiatric practices are somewhat discretionary and sensitive to practice cash flows and financing availability during recessions. However, mental health treatment demand is relatively recession-resistant and may increase during economic stress. The 72% gross margin provides buffer, but negative operating margins create vulnerability to revenue shortfalls.

Rising rates negatively impact the business through multiple channels: (1) higher financing costs for practices purchasing $60K-$80K systems reduce affordability, (2) increased cost of capital compresses valuation multiples for unprofitable growth companies, (3) higher discount rates reduce NPV of future recurring revenue streams. The 3.32 debt/equity ratio indicates material interest expense sensitivity.

growth - Attracts speculative investors betting on mental health market expansion, TMS adoption acceleration, and path to profitability. The -72.6% one-year return and -61.3% six-month return reflect high-risk, high-reward profile. Not suitable for value or income investors given negative earnings, no dividend, and elevated debt levels. Requires conviction in neuromodulation TAM expansion and company's ability to achieve scale.